Author:
Liu Lanting,Yu Zhen,Cheng Hui,Mao Xuehan,Sui Weiwei,Deng Shuhui,Wei Xiaojing,Lv Junqiang,Du Chenxing,Xu Jie,Huang Wenyang,Xia Shuang,An Gang,Zhou Wen,Ma Xiaoke,Cheng Tao,Qiu Lugui,Hao Mu
Abstract
AbstractAnaemia is the most common complication of myeloma and is associated with worse clinical outcomes. Although marrow replacement with myeloma cells is widely considered a mechanistic rationale for anaemia, the exact process has not been fully understood. Our large cohort of 1363 myeloma patients had more than 50% of patients with moderate or severe anaemia at the time of diagnosis. Anaemia positively correlated with myeloma cell infiltration in the bone marrow (BM) and worse patient outcomes. The quantity and erythroid differentiation of HSPCs were affected by myeloma cell infiltration in the BM. The master regulators of erythropoiesis, GATA1 and KLF1, were obviously downregulated in myeloma HSPCs. However, the gene encoding the chemokine CCL3 showed significantly upregulated expression. Elevated CCL3 in the BM plasma of myeloma further inhibited the erythropoiesis of HSPCs via activation of CCL3/CCR1/p38 signalling and suppressed GATA1 expression. Treatment with a CCR1 antagonist effectively recovered GATA1 expression and rescued erythropoiesis in HSPCs. Myeloma cell infiltration causes elevated expression of CCL3 in BM, which suppresses the erythropoiesis of HSPCs and results in anaemia by downregulating the level of GATA1 in HSPCs. Thus, our study indicates that targeting CCL3 would be a potential strategy against anaemia and improve the survival of myeloma patients.
Funder
the Fundamental Research Funds for the Central Universities
Natural Science Foundation of China
Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
Tianjin Science and Technology Supporting Program
the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).
2. Kawano, Y., Roccaro, A. M., Ghobrial, I. M. & Azzi, J. Multiple myeloma and the immune microenvironment. Curr. Cancer Drug Targets 17(9), 806–818 (2017).
3. Konig, C. et al. Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS–and stem cell transplant (SCT)–patients?. Clin. Lymphoma Myeloma Leuk. 13(6), 671–680 (2013).
4. Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113(9), 1271–1276 (2004).
5. Goodnough, L. T., Nemeth, E. & Ganz, T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116(23), 4754–4761 (2010).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献